Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma

Journal of Surgical Oncology

Volumn 106, Issue 2, 2012, Pages 174-180

  Murakami, Yoshiaki ^a   Uemura, Kenichiro ^a   Sudo, Takeshi ^a   Hashimoto, Yasushi ^a   Nakashima, Akira ^a   Kondo, Naru ^a   Nakagawa, Naoya ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

adjuvant chemotherapy; gemcitabine; overall survival; pancreatic carcinoma; S 1

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863726640     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23068     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Sener SF, Fremgen A, Menck HR, et al.: Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7. (Pubitemid 29307735)
3. Murakami Y, Uemura K, Sudo T, et al.: Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010; 211: 196-204.
4. Winter JM, Cameron JL, Campbell KA, et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-1211. (Pubitemid 44781200)
5. Matsuno S, Egawa S, Fukuyama S, et al.: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004; 28: 219-230. (Pubitemid 38437313)
6. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
7. Farnell MB, Pearson RK, Sarr MG, et al.: Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618-630. (Pubitemid 41546183)
8. Yeo CJ, Cameron JL, Sohn TA, et al.: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term outcome. Ann Surg 1999; 229: 613-624. (Pubitemid 30187568)
9. Pedrazzoli S, DiCarlo V, Dionigi R, et al.: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517. (Pubitemid 30194394)
10. Neoptolemos JP, Stocken DD, Bassi C, et al.: European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine followed pancreatic cancer resection: A randomized controlled trial. JAMA 2010; 304: 1073-1081.
11. Van Laethem JL, Hammel P, Mornex F, et al.: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-2201 2/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28: 4450-4456.
12. Regine WF, Winter KA, Abrams RA, et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008; 299: 1019-1026. (Pubitemid 351347058)
13. Ueno H, Kosuge T, Matsuyama Y, et al.: A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for pancreatic cancer. Br J Cancer 2009; 101: 908-915.
14. Yoshitomi H, Togawa A, Kimura F, et al.: Pancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital Group. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008; 113: 2448-2456.
15. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277. (Pubitemid 46143304)
16. Kosuge T, Kiuchi T, Mukai K, et al.: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165.
17. Neoptolemos JP, Stocken DD, Friess H, et al.: European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210. (Pubitemid 38339364)
18. Takada T, Amano H, Yasuda H, et al.: Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695.
19. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-784. (Pubitemid 30191812)
20. Bakkevold KE, Arnesjo B, Dahl O, et al.: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of VaterâResults of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703. (Pubitemid 23077048)
21. Gastrointestinal Tumour Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006-2010.
22. Herman JM, Swartz MJ, Hsu CC, et al.: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-3510.
23. Corsini MM, Miller RC, Haddock MG, et al.: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26: 3511-3516.
24. Murakami Y, Uemura K, Sudo T, et al.: Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg 2008; 195: 757-762. (Pubitemid 351749450)
25. Shirasaka T, Shimamato Y, Ohshimo H, et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557. (Pubitemid 26276346)
26. Ueno H, Okusaka T, Ikeda M, et al.: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 2005; 69: 421-427. (Pubitemid 41797919)
27. Nakamura K, Yamaguchi T, Ishihara T, et al.: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-1579. (Pubitemid 43924916)
28. Murakami Y, Uemura K, Sudo T, et al.: Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009; 250: 950-956.
29. Murakami Y, Uemura K, Hayashidani Y, et al.: Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007; 95: 207-212.
30. Sudo T, Murakami Y, Uemura K, et al.: Prognostic impact of perineural invasion following pancreatoduodenectomy with lymphadenectomy for ampullary carcinoma. Dig Dis Sci 2008; 53: 2281-2286.
31. Murakami Y, Uemura K, Ohge H, et al.: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery 2006; 140: 443-453.
32. Murakami Y, Uemura K, Sudo T, et al.: Prognostic impact of para-aortic lymph node metastasis in pancreatic carcinoma. World J Surg 2010; 34: 1900-1907.
33. Sobin LH, Gospodarowicz MK, Wittekind C, editors: International Union Against Cancer (UICC): TNM classification of malignant tumours, 7th edition. New York: Wiley-Blackwell; 2010.
34. Picozzi VJ, Abrams RA, Decker PA, et al.: American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011; 22: 348-354.
35. Linehan DC, Tan MC, Strasberg SM, et al.: Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution phase II study. Ann Surg 2008; 248: 145-151.
36. Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-636. (Pubitemid 28079110)
37. Ioka T, Ikeda S, Ohkawa H, et al.: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 2011; 29: abstr 4007.
38. Berger AC, Garcia M, Jr., Hoffman JP, et al.: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 2008; 26: 5918-5922.
39. Kondo N, Murakami Y, Uemura K, et al.: Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer. Ann Surg Oncol 2010; 17: 2321-2329.
40. Cunningham D, Chau I, Stocken DD, et al.: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518.